Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Free Cash Flow (2020 - 2025)

Xeris Biopharma Holdings' Free Cash Flow history spans 6 years, with the latest figure at $20.0 million for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 914.84% year-over-year to $20.0 million, compared with a TTM value of $28.6 million through Dec 2025, up 177.41%, and an annual FY2025 reading of $28.6 million, up 177.41% over the prior year.
  • Free Cash Flow for Q4 2025 was $20.0 million at Xeris Biopharma Holdings, up from $18.4 million in the prior quarter.
  • The five-year high for Free Cash Flow was $20.0 million in Q4 2025, with the low at -$48.4 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$12.7 million, with a median of -$15.4 million recorded in 2022.
  • Year-over-year, Free Cash Flow plummeted 162.1% in 2021 and then surged 914.84% in 2025.
  • Tracing XERS's Free Cash Flow over 5 years: stood at -$29.1 million in 2021, then surged by 44.56% to -$16.1 million in 2022, then soared by 146.35% to $7.5 million in 2023, then plummeted by 73.56% to $2.0 million in 2024, then surged by 914.84% to $20.0 million in 2025.
  • Per Business Quant, the three most recent readings for XERS's Free Cash Flow are $20.0 million (Q4 2025), $18.4 million (Q3 2025), and $182000.0 (Q2 2025).